Study Objective: Kleine-Levin syndrome (KLS) is a rare disease of unknown etiology, the diagnosis of which can be challenging. We aimed to estimate KLS prevalence in French-speaking Switzerland, and assess differences with mimicking conditions. Methods: In this cross-sectional study, KLS patients were identified through a population-based approach, including at our hospital and contacting all sleepcertified facilities and neurologists in French-speaking Switzerland. Furthermore, we identified patients referred to our center for suspected KLS that received other diagnoses. Relevant clinical data of these two groups was compared. Results: We identified 7 patients with diagnosed KLS (6 since 2009), leading to a prevalence estimation of 3.19 per million (95% confidence interval: 1.55-6.59). Median age at diagnosis was 17 years (range: 12-19), 71.4% of them were men, and mean diagnosis delay after the first episode was 20.1 ± 10.9 months. We identified 9 mimic patients referred to our center; they differed from KLS patients by their higher age at disease onset (median: 15 [range: 12-16] vs. 19 [range: 16-64] years; p < 0.001), suspected KLS as referral reason (more frequent in mimics, p = 0.003), and the presence of precipitating factors (more frequent in KLS, p = 0.011). Among the mimic patients, 77% (versus 28% in KLS) had a psychiatric diagnosis. Conclusions: This study suggests a relatively higher KLS prevalence than previously reported. As compared to KLS, mimic patients have higher age at symptom onset, are more often initially referred for KLS suspicion, and have a higher prevalence of psychiatric disorders.
been confirmed in a larger cohort. 2, 12 To date, no placebo-controlled trials concerning treatment management are available, although lithium seems to be the most efficacious prophylactic drug for patients with frequent and disabling episodes. 2, 11, 13, 14 The prevalence of KLS, classically estimated at 1 per million, has been recently evaluated at 1.8 cases per million in France. 8 At our center, we currently follow several KLS patients, which led us to suspect a higher prevalence than described in the literature. Moreover, in recent years we also ruled out KLS diagnosis in a consistent number of patients referred for this suspicion.
BRIEF SUMMARY
Current Knowledge/Study Rationale: Kleine-Levin syndrome (KLS) is a rare disease of uncertain prevalence, for which no recognized biological marker has been identified making its diagnosis difficult. The aim of our study was to estimate the prevalence of KLS in French-speaking Switzerland, and to characterize the typical clinical presentation of these patients as compared to patients with mimicking diagnoses. Study Impact: This study estimates the prevalence of KLS at 3.19 per million, which is moderately higher than previously published. Compared to confirmed KLS cases, patients with mimicking conditions tend to be older at disease onset, show no gender predominance, report less frequently precipitating factors and have a higher prevalence of psychiatric disorders.
The aim of our study was to estimate the prevalence of KLS in the French-speaking part of Switzerland, and to characterize the typical clinical presentation of these patients as compared to patients with mimicking diagnoses, among whom KLS was first suspected but finally ruled out.
M ETHO DS

Design and Subjects
In this cross-sectional study, data from all patients referred to our center for recurrent episodes of hypersomnia or KLS between November 2006 and August 2015 were retrospectively reviewed. Additionally, all private practice neurologists and sleep specialists working in certified sleep centers of the French-speaking part of Switzerland, including the Cantons of Vaud, Neuchâtel, Jura, Geneva, Fribourg, Valais (Frenchspeaking districts), and Bern (French-speaking districts) were asked if KLS patients living in the French-speaking side of the country were diagnosed and/or followed. The Vaud Cantonal Ethics Committee on research involving humans approved the study.
Data Collection
For patients fulfilling the KLS criteria of the International Classification of Sleep Disorders, 1 we collected data concerning: demographics, time of first episode, time of diagnosis, number and duration of episodes, interval between episodes and time since the last relapse, pharmacological treatment, precipitant factors, and disease evolution (relapsing remitting vs long episodes). We indexed the first symptoms of the disease and the referral reason, the presence of hypersomnia (at least in 2 episodes), cognitive, eating, sexuality-related disorders, and behavioral or psychological disturbances. We also retrieved current therapy and the presence of medical comorbidities. For patients referred for suspected KLS but for which this diagnosis was not confirmed ("mimics"), we collected the following data: demographics, final diagnosis, precipitant factors, first symptoms of the disease, referral reason, the presence of cognitive, eating, sexually related, behavioral, or psychological disturbances, and the presence of comorbidities. When available, we also reviewed data from complementary investigations, including brain MRI, PET-CT, standard EEG, polysomnographic recordings, multiple sleep latency test, actigraphy, biological measures, CSF examination, and neuropsychological investigations.
Statistical Analysis
Comparisons between groups were performed using Mann-Whitney U tests or two-tailed Fisher exact tests, as needed. The prevalence was calculated (using the Wilson method for the confidence interval, in view of the low numbers), with data provided by the Swiss Federal Statistics Office (Federal Statistical Office, Neuchâtel 2015, accessed on September 28 th 2015, http://www.bfs.admin.ch/bfs/portal/fr/index.html). The number of inhabitants in 2014 (in parentheses) of the Cantons of Fribourg (303,337), Geneva (477,385), Jura (72,410), Neuchâtel (177,327), and Vaud (761,446) were included. Concerning the Bern and Valais cantons, only the French-speaking districts were considered (respectively: 151,246 and 249,479). The total number of inhabitants used to calculate the prevalence in the French-speaking Switzerland was 2,192,670. We did not correct for multiple comparisons, given the exploratory character of this study. The comparison between prevalence of KLS in French-speaking Switzerland and France was assessed using a likelihood ratio χ 2 test.
R ESU LT S
We identified 7 patients with KLS according to the International Classification of Sleep Disorder, Third Edition criteria, 1 and 9 mimic cases, whose details are summarized in Tables 1  and 2 . Apart from a patient formerly diagnosed in 2002, all other subjects were diagnosed since 2009.
Prevalence of KLS
The estimated prevalence in the French-speaking part of Switzerland was 3.19 per million (95% confidence interval: 1.55-6.59); this was not statistically different from the estimate of 1.8 per million in France (p = 0.148). 8 Five subjects were living in the canton of Vaud, and the remaining two in Fribourg and Valais (see Figure S1 in the supplemental material).
KLS Patient Characteristics
Six patients were diagnosed and followed up at our center (2 young women); one additional man was identified in Valais. Mean age at diagnosis was 17 years (range: [12] [13] [14] [15] [16] [17] [18] [19] . Table 1 shows their clinical characteristics. Two young men presented unfavorable courses, with progressively more frequent and longer episodes (in one patient, an episode lasted over one year), and shorter illness-free intervals. The 5 other patients experienced a typical relapsing-remitting course. One subject was not taking any treatment, one methylphenidate and lamotrigine, and the other 5 were taking lithium (2 with additional compounds: escitalopram and amantadine in one each); an increase in duration of disease-free intervals were observed in 3 patients taking lithium. We observed a recurrence upon lithium weaning in one of them, while in 2 patients, lithium possibly led to a remission. Two patients had a psychiatric comorbidity ( Table 2) . Extensive complementary investigations were normal or showed nonspecific abnormalities, and did not enable specific distinction between KLS and mimics patients.
Mimic Patients and Differences from KLS
In our center, we detected 9 subjects (4 women); their median age at diagnosis was 26 years (range: 17-64). Seven mimic patients finally had psychiatric diagnoses, while the 2 remaining patients had idiopathic hypersomnia and a circadian sleep disorder. Table 2 highlights differences between KLS and mimics patients. Clinical characteristics including cognitive symptoms, eating disorders, behavioral disturbances, and sexually related disorders were only observed during episodes concerning KLS patients. Among mimic patients, a clear distinction between episodes and disease-free interval was somehow difficult, as they mainly presented a progressive fluctuation in the severity of clinical symptomatology, compared to KLS patients. Two KLS patients, who reported unfavorable courses, presented symptoms such as hypersomnia and excessive daytime sleepiness in disease-free intervals after, respectively, 40 and 23 disabling episodes. At symptom onset, KLS patients were significantly younger than mimic patients. Subjects with KLS were referred for suspicion of viral encephalitis or epilepsy, feverish state of unknown origin, mental slowness, and idiopathic hypersomnia, whereas the majority of mimic patients were specifically referred for KLS suspicion. While all KLS patients presented at least a precipitating factor, only 3 mimic patients reported one (an influenza-like infection, 2 emotional stress). Other clinical characteristics reported in Table 2 did not show any remarkable differences.
DISCUSSI ON
This study estimates the prevalence of KLS in the Frenchspeaking part of Switzerland at 3.19 per million (95% CI: 1.55-6.59), and highlights the differences between defined KLS patients and mimics: mimics tended to be older at disease onset with no major gender predominance, and they were mainly referred specifically for KLS suspicion, with less frequent reports of a precipitating factor. The definite diagnosis provided for mimics was, in most cases, a psychiatric disorder.
Our estimated KLS prevalence seems somewhat higher than previously published data: 1.5 per million worldwide, 13 and 1.8 per million in France, 8 but the difference is not statistically significant compared to France. The geographical distribution of KLS patients and the marked overrepresentation of subjects from the canton of Vaud may suggest that this entity could remain underdiagnosed in some areas with limited access to specialized centers. We might still have missed some KLS patients, despite contacting all certified sleep centers and neurologist in the study region; alternatively, a yet unidentified factor related to genetics or exposure could be at play-indeed, KLS prevalence also strongly varies across French regions. 8 The mean latency of diagnosis of KLS patients in our study (20 months) appears shorter than previously described: about 4 years in 2001 (in Israel), 15 and 2 years in 2011 (in France), 10 and may suggest a natural fluctuation, or that increasing KLS awareness may influence diagnosis. However, the fact that in our study 6 of 7 patients have been diagnosed after 2009 favors the second hypothesis. Further studies might estimate if the density of sleep specialists or centers in a given territory may play a role in this extent.
The clinical presentation of KLS patients may be difficult to distinguish from mimics. Our study shows that the latter are mostly related to various psychiatric disorders. Marked differences between KLS patients and mimic cases were observed in the referral reasons: while KLS patients had a suspicion of viral encephalitis, epilepsy, mental slowness, or hypersomnia, the majority of mimic patients were specifically referred for KLS suspicion. This underscores the need for patients with KLS suspicion to undergo a formal neurologic and a psychiatric interview as recently pointed out. 8 KLS patients were also younger at symptom onset. The age at disease onset in our KLS cohort is similar to previously reported cases, 2,10,11,13 underscoring its predominantly adolescent onset. 11, 13, 16 The significant difference regarding triggers should be viewed cautiously, as some KLS patients reported in the literature did not remember precipitant events and, given the nature of our ascertainment, a recall bias is not formally excluded. 2, 13 Finally, in our center, mimic patients outnumbered KLS patients, as opposed to a recent French nationwide publication. 8 While this may reflect a referral bias or a geographical specific characteristic, it can prove relevant for practicing sleep specialists and neurologists.
All KLS patients described cognitive impairment, but none reported sexually related disorders; a minority had ictal megaphagia, or appetite loss. This emphasizes the importance of cognitive disorders, specifically derealization, as one of the core symptoms of KLS, and that sexual-related disorders are only inconstantly found as opposed to the original descriptions. 2, [8] [9] [10] [11] Concerning treatment, five KLS patients were taking lithium on a long-term basis; all reported improvement, with longer disease-free intervals in four and even lack of relapses for, respectively, 40 and 11.5 months until August 2015 in two. In one patient, a recurrence was observed upon progressive lithium weaning, and a good response was obtained after lithium increase, as previously reported. 2, 11, 13, 14, 17, 18 In two patients, however, unfavorable courses were observed: their episodes became progressively more frequent and longer, resulting in shorter illness-free intervals. This evolution seems to be more frequent than previously described, also in the light of a recent study on a large KLS cohort, 8 and challenges the idea of KLS representing a "benign" disease.
To the best of our knowledge, this is the first populationbased study assessing KLS prevalence not only in Switzerland, but outside France 8 (and one worldwide estimation from previously published cases 13 ) and points to a possibly increasing prevalence of KLS, at least in some European regions. The characterization of clinical presentations and course of KLS provides clues to differentiate defined KLS patients and potentially mimics patients.
However, we acknowledge potential limitations. Its retrospective design prevented an optimal data ascertainment in each patient, and the diagnostic workup was not uniform. The sample size was also relatively small, and we could not find many statistically significant differences. Despite our efforts to personally contact every neurologist and sleep facility potentially treating KLS patients, undiagnosed subjects or patients followed only by their general practitioner may have been missed; given the complexity of the KLS follow-up we believe that the second possibility is highly unlikely. While we used a population-based approach regarding KLS patients, mimics patients were only recruited in our hospital: while this prevented an estimation of the prevalence of mimics, we believe that comparisons between these two groups are valid, as they reflect clinical management in real practice, and as 6 of the 7 patients with KLS are followed in our center. Finally, the relatively higher KLS prevalence in this study should be seen in the context of a very rare disease, whose prevalence may fluctuate, depending on local awareness and better clinical characterization in recent years, pointing out for example to a relatively frequent lack of hypersexuality. 2, 8, 11 
